What is TSLP asthma?

TSLP is a pleiotropic cytokine that is expressed at barrier surfaces, such as the lung, and plays an important role in allergic inflammation and asthma.

What are monoclonal antibodies for asthma?

Monoclonal antibodies are produced by clonal B cells, bind to a single specific epitope, and can be used to target and block specific molecule functions. Omalizumab binds IgE and is approved for the treatment of severe allergic asthma. Treatment reduces exacerbations requiring OCS treatment and hospitalisations.

What monoclonal antibody therapies have been developed for the treatment of asthma?

Omalizumab. Omalizumab is the only monoclonal antibody licensed for severe asthma that directly targets IgE.

How do Monoclonal Antibodies work for asthma?

Monoclonal antibodies (biologicals) are increasingly emerging as targeted therapies that block specific molecular pathways in severe asthma. Monoclonal antibodies work by binding to and blocking the function of a specific target molecule (e.g. anti-IgE or anti-interleukin-5).

Is tezepelumab approved for asthma?

AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.

How do you treat TSLP?

TSLP has been implicated in asthma pathophysiology. Tezepelumab is a first-in-class human monoclonal antibody that binds to TSLP, thus inhibiting its interaction with TSLP receptor complex. Tezepelumab given as an add-on-therapy to patients with severe uncontrolled asthma has shown safety, tolerability and efficacy.

What does IgE do in asthma?

IgE binds to high-affinity receptors (FcϵRI) on effector cells, such as mast cells and basophils. Allergen binds to IgE and initiates an inflammatory cascade resulting in release of pro-inflammatory mediators that contribute to the acute and chronic symptoms of allergic airway diseases.

What is type2 asthma?

Type 2 asthma is characterised by Type 2 inflammation and typically includes allergic asthma, exercise-induced asthma, and late-onset eosinophilic asthma. Understanding of allergic, eosinophilic, and mixed allergic/eosinophilic phenotypes has greatly advanced and may underpin new approaches to improve asthma control.

What is the new treatment for asthma?

DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing.